Immunotherapy in Myeloproliferative Diseases
| Autor: | Lukas Braun, Robert Zeiser |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_treatment MPN MDSCs Review myeloproliferation 03 medical and health sciences 0302 clinical medicine Immune system AML hemic and lymphatic diseases allo-HSCT medicine MDS Humans tumor vaccination immune checkpoint lcsh:QH301-705.5 Myeloproliferative Disorders business.industry Myelodysplastic syndromes immune escape Myeloid leukemia General Medicine Immunotherapy medicine.disease Immune checkpoint 3. Good health Transplantation Leukemia 030104 developmental biology medicine.anatomical_structure JAK2 lcsh:Biology (General) inflammation 030220 oncology & carcinogenesis CD123 Cancer research Bone marrow immunotherapy business IFNα |
| Zdroj: | Cells, Vol 9, Iss 1559, p 1559 (2020) Cells |
| ISSN: | 2073-4409 |
| Popis: | Myeloproliferative diseases, including myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS), are driven by genetic abnormalities and increased inflammatory signaling and are at high risk to transform into acute myeloid leukemia (AML). Myeloid-derived suppressor cells were reported to enhance leukemia immune escape by suppressing an effective anti-tumor immune response. MPNs are a potentially immunogenic disease as shown by their response to interferon-α treatment and allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Novel immunotherapeutic approaches such as immune checkpoint inhibition, tumor vaccination, or cellular therapies using target-specific lymphocytes have so far not shown strong therapeutic efficacy. Potential reasons could be the pro-inflammatory and immunosuppressive microenvironment in the bone marrow of patients with MPN, driving tumor immune escape. In this review, we discuss the biology of MPNs with respect to the pro-inflammatory milieu in the bone marrow (BM) and potential immunotherapeutic approaches. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|